var title_f32_34_33312="Ketoconazole: Drug information";
var content_f32_34_33312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketoconazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/58/28585?source=see_link\">",
"       Ketoconazole (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38500?source=see_link\">",
"       Ketoconazole (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8589 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33312=[""].join("\n");
var outline_f32_34_33312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/58/28585?source=related_link\">",
"      Ketoconazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38500?source=related_link\">",
"      Ketoconazole (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_34_33313="Large horizontal overjet";
var content_f32_34_33313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Large horizontal overjet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &copy; Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33313=[""].join("\n");
var outline_f32_34_33313=null;
var title_f32_34_33314="Excessive femoral anteversion";
var content_f32_34_33314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Excessive femoral anteversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Femoral anteversion is the angular difference between the axis of the femoral neck and the transcondylar axis of the femur. In this photograph, the femur on the right has normal anteversion: the plane of the proximal femur (the femoral head, neck and greater trochanter) is about 10 to 15 degrees anterior to the plane of the femoral condyles of the distal femur. The femur on the left has excessive femoral anteversion: the plane of the proximal femur is about 60 degrees from the plane of the distal femur. Note that as the femoral head rotates anteriorly, the greater trochanter rotates posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33314=[""].join("\n");
var outline_f32_34_33314=null;
var title_f32_34_33315="Valrubicin: Patient drug information";
var content_f32_34_33315=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Valrubicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22292?source=see_link\">",
"     see \"Valrubicin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Valstar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Valtaxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bladder cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703116",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to valrubicin, other anthracycline drugs, polyoxyl castor oil, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703692",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Torn bladder, small bladder, or a bladder infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you had a bladder treatment or surgery less than 2 weeks ago.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697898",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697958",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to orange or red.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder pain or pain when passing urine or change in how much urine is passed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain when passing urine or blood in urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12224 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33315=[""].join("\n");
var outline_f32_34_33315=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233115\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233116\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022302\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022301\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022306\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022307\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022309\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022304\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022305\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022310\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022311\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22292?source=related_link\">",
"      Valrubicin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_34_33316="Lactulose: Drug information";
var content_f32_34_33316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lactulose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/59/19380?source=see_link\">",
"    see \"Lactulose: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=see_link\">",
"    see \"Lactulose: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Constulose;",
"     </li>",
"     <li>",
"      Enulose;",
"     </li>",
"     <li>",
"      Generlac;",
"     </li>",
"     <li>",
"      Kristalose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acilac;",
"     </li>",
"     <li>",
"      Apo-Lactulose&reg;;",
"     </li>",
"     <li>",
"      Laxilose;",
"     </li>",
"     <li>",
"      PMS-Lactulose",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ammonium Detoxicant;",
"     </li>",
"     <li>",
"      Laxative, Osmotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Oral: 10-20 g (15-30 mL) daily; may increase to 40 g (60 mL) daily if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of portal systemic encephalopathy (PSE):",
"     </b>",
"     Oral: 20-30 g (30-45 mL) 3-4 times/day; adjust dose every 1-2 days to produce 2-3 soft stools/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of acute PSE:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 20-30 g (30-45 mL) every 1 hour to induce rapid laxation; reduce to 20-30 g (30-45 mL) 3-4 times/day after laxation is achieved titrate to produce 2-3 soft stools/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal administration (retention enema): 200 g (300 mL) diluted with 700 mL of  water or NS via rectal balloon catheter; retain for 30-60 minutes; may repeat every 4-6 hours; transition to oral treatment prior to discontinuing rectal administration",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F186566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=see_link\">",
"      see \"Lactulose: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of portal systemic encephalopathy (PSE):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 1.7-6.7 g/day (2.5-10 mL/day) in divided doses; adjust dosage to produce 2-3 stools/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 26.7-60 g/day (40-90 mL/day) in divided doses; adjust dosage to produce 2-3 stools/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Constipation (unlabeled use):",
"     </b>",
"     Oral: 0.7-2 g/kg/day (1-3 mL/kg/day) in divided doses, maximum: 40 g/day (60 mL/day) (NASPGHAN, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Crystals for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kristalose&reg;: 10 g/packet (30s); 20 g/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 10 g/15 mL (15 mL, 30 mL, 237 mL, 473 mL, 500 mL, 946 mL, 1892 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Constulose: 10 g/15 mL (237 mL [DSC], 946 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enulose: 10 g/15 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral/rectal: 10 g/15 mL (237 mL, 473 mL, 946 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Generlac: 10 g/15 mL (473 mL, 1892 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes crystals for solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F186527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: May mix with fruit juice, water or milk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crystals for oral solution: Dissolve contents of packet in 120 mL water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal: Mix with water or normal saline; administer as retention enema using a rectal balloon catheter; retain for 30-60 minutes. Transition to oral lactulose when appropriate (able to take oral medication and no longer a risk for aspiration) prior to discontinuing rectal administration",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of portal-systemic encephalopathy (including hepatic precoma and coma); treatment of constipation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lactulose may be confused with lactose",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Dehydration, hypernatremia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal discomfort, abdominal distention, belching, cramping, diarrhea (excessive dose), flatulence, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in patients requiring a low galactose diet",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Monitor periodically for electrolyte imbalance when lactulose is used &gt;6 months or in patients predisposed to electrolyte abnormalities (eg, elderly). Hepatic disease may predispose patients to electrolyte imbalance. Infants receiving lactulose may develop hyponatremia and dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; solution contains galactose and lactose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anti-infectives (oral): Patients receiving lactulose and an oral anti-infective agent should be monitored for possible inadequate response to lactulose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrocautery procedures: During proctoscopy or colonoscopy procedures involving electrocautery, a theoretical risk of reaction between H",
"     <sub>",
"      2",
"     </sub>",
"     gas accumulation and electrical spark may exist; thorough bowel cleansing with a nonfermentable solution is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13763432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F186550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F186533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients on galactose-restricted diet; may be mixed with fruit juice, milk, water, or citrus-flavored carbonated beverages.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F186532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Kristalose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (30): $82.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 g (30): $96.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lactulose Encephalopathy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/15 mL (473 mL): $36.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lactulose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/15 mL (473 mL): $34.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F186521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, standing/supine; serum electrolytes, serum ammonia; bowel movement patterns, fluid status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F186534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actilax (AU);",
"     </li>",
"     <li>",
"      Amivalex (HU);",
"     </li>",
"     <li>",
"      Bifiteral (BE, DE, LU);",
"     </li>",
"     <li>",
"      Constipen (ID);",
"     </li>",
"     <li>",
"      Danilax (HK);",
"     </li>",
"     <li>",
"      Dhactulose (HK, MY, SG);",
"     </li>",
"     <li>",
"      Dia-Colon (IT);",
"     </li>",
"     <li>",
"      Dismam L (PE);",
"     </li>",
"     <li>",
"      Duphalac (AE, AT, AU, BE, BG, BH, CL, CN, CY, CZ, EC, EE, EG, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IQ, IR, IT, JO, KP, KW, LB, LU, LY, MY, NL, NO, NZ, OM, PE, PH, PK, PL, PT, PY, QA, RU, SA, SE, SG, SY, TH, TR, TW, YE, ZA);",
"     </li>",
"     <li>",
"      Farlac (BR);",
"     </li>",
"     <li>",
"      Genlac (AU);",
"     </li>",
"     <li>",
"      Genocolan (AR);",
"     </li>",
"     <li>",
"      Hepalac (TH);",
"     </li>",
"     <li>",
"      Lac-Dol (AU);",
"     </li>",
"     <li>",
"      Lacoly (TW);",
"     </li>",
"     <li>",
"      Lacons (ID);",
"     </li>",
"     <li>",
"      Lacson (ZA);",
"     </li>",
"     <li>",
"      Lactocur (LU);",
"     </li>",
"     <li>",
"      Lactul (MY, PH, TW);",
"     </li>",
"     <li>",
"      Lactulax (EC, ID, MX, UY);",
"     </li>",
"     <li>",
"      Lactulen (CO);",
"     </li>",
"     <li>",
"      Lactulosa (EC);",
"     </li>",
"     <li>",
"      Lactulose-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Lactumed (MY);",
"     </li>",
"     <li>",
"      Lactus (SG);",
"     </li>",
"     <li>",
"      Lactuverlan (DE);",
"     </li>",
"     <li>",
"      Laevolac (AT, CL, HK, HN, IL, IT, NZ, PT, TH);",
"     </li>",
"     <li>",
"      Laxadilac (ID);",
"     </li>",
"     <li>",
"      Laxal (PE);",
"     </li>",
"     <li>",
"      Laxalan (PE);",
"     </li>",
"     <li>",
"      Laxette (ZA);",
"     </li>",
"     <li>",
"      Legendal (CH);",
"     </li>",
"     <li>",
"      Levolac (FI, NO);",
"     </li>",
"     <li>",
"      Lidong (CL);",
"     </li>",
"     <li>",
"      Lilac (PH);",
"     </li>",
"     <li>",
"      Lipebin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, PE, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Livo Luk (IN);",
"     </li>",
"     <li>",
"      Losalac (TH);",
"     </li>",
"     <li>",
"      Medilax (DK);",
"     </li>",
"     <li>",
"      Moderan (VE);",
"     </li>",
"     <li>",
"      Monilac (JP);",
"     </li>",
"     <li>",
"      Movelax (PH);",
"     </li>",
"     <li>",
"      Normase (IL);",
"     </li>",
"     <li>",
"      Normolax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Portalak (HR);",
"     </li>",
"     <li>",
"      Pralax (ID);",
"     </li>",
"     <li>",
"      Regulact (MX);",
"     </li>",
"     <li>",
"      Rilax (PH);",
"     </li>",
"     <li>",
"      Sarex (TH);",
"     </li>",
"     <li>",
"      Solac (ID);",
"     </li>",
"     <li>",
"      Tenualax (AR);",
"     </li>",
"     <li>",
"      Tulotract (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The bacterial degradation of lactulose resulting in an acidic pH inhibits the diffusion of NH",
"     <sub>",
"      3",
"     </sub>",
"     into the blood by causing the conversion of NH",
"     <sub>",
"      3",
"     </sub>",
"     to NH",
"     <sub>",
"      4",
"     </sub>",
"     +; also enhances the diffusion of NH",
"     <sub>",
"      3",
"     </sub>",
"     from the blood into the gut where conversion to NH",
"     <sub>",
"      4",
"     </sub>",
"     + occurs; produces an osmotic effect in the colon with resultant distention promoting peristalsis; reduces blood ammonia concentration to reduce the degree of portal systemic encephalopathy",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Constipation: Up to 24-48 hours to produce a normal bowel movement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Encephalopathy: At least 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Not appreciable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via colonic flora to lactic acid and acetic acid; requires colonic flora for drug activation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine (&le;3%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Evaluation and Treatment of Constipation in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2006, 43(3):e1-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/34/33316/abstract-text/16954945/pubmed\" id=\"16954945\" target=\"_blank\">",
"        16954945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lederle FA, Busch DL, Mattox KM, et al, &ldquo;Cost-Effective Treatment of Constipation in the Elderly: A Randomized Double-Blind Comparison of Sorbitol and Lactulose,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1990, 89(5):597-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/34/33316/abstract-text/2122724/pubmed\" id=\"2122724\" target=\"_blank\">",
"        2122724",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9543 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.102.30.19-FFD0E59FF1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33316=[""].join("\n");
var outline_f32_34_33316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186541\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186542\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186584\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186545\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186566\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186546\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160250\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160251\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186523\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186508\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186527\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186526\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186591\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186582\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186530\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186512\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299571\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186517\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186519\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13763432\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186550\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186533\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186532\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186521\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186534\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186511\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186529\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/59/19380?source=related_link\">",
"      Lactulose: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=related_link\">",
"      Lactulose: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_34_33317="Mesalamine (mesalazine): Patient drug information";
var content_f32_34_33317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mesalamine (mesalazine): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     see \"Mesalamine (mesalazine): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/5/27734?source=see_link\">",
"     see \"Mesalamine (mesalazine): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Apriso&trade;;",
"     </li>",
"     <li>",
"      Asacol&reg; HD;",
"     </li>",
"     <li>",
"      Asacol&reg; [DSC];",
"     </li>",
"     <li>",
"      Canasa&reg;;",
"     </li>",
"     <li>",
"      Delzicol&trade;;",
"     </li>",
"     <li>",
"      Lialda&reg;;",
"     </li>",
"     <li>",
"      Pentasa&reg;;",
"     </li>",
"     <li>",
"      Rowasa&reg;;",
"     </li>",
"     <li>",
"      sfRowasa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      5-ASA;",
"     </li>",
"     <li>",
"      Asacol&reg;;",
"     </li>",
"     <li>",
"      Asacol&reg; 800;",
"     </li>",
"     <li>",
"      Mesasal&reg;;",
"     </li>",
"     <li>",
"      Mezavant&reg;;",
"     </li>",
"     <li>",
"      Novo-5 ASA;",
"     </li>",
"     <li>",
"      Novo-5 ASA-ECT;",
"     </li>",
"     <li>",
"      Pentasa&reg;;",
"     </li>",
"     <li>",
"      Salofalk&reg;;",
"     </li>",
"     <li>",
"      Salofalk&reg; 5-ASA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691957",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mild to moderate disease at the far end of the colon.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702476",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mesalamine, salicylates, sulfasalazine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an inflamed pancreas, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an inflamed sac around the heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ulcer disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696850",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take Apriso&trade; with antacids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697652",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The rectal drug may stain fabric, flooring, painted surfaces, marble, granite, vinyl, and enamel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you see tablet bits in the stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695374",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mezavant&reg; and Lialda&reg;: Take with a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet or capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696198",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository or suspension rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep suspension in your rectum as long as you can.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take foil off the rectal suppository and put in, pointed end first. Do not handle too much. Keep in your rectum for at least 3 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You could be on both a tablet or capsule and a rectal product at the same time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699532",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store rectal suspension in foil until ready to use. Do not refrigerate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect rectal suspension from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect rectal suspension from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699170",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if suspension changes color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10842 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-1F4CD360AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33317=[""].join("\n");
var outline_f32_34_33317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193412\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193413\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025709\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025708\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025713\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025714\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025716\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025711\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025712\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025717\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025718\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=related_link\">",
"      Mesalamine (mesalazine): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/5/27734?source=related_link\">",
"      Mesalamine (mesalazine): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_34_33318="Isotretinoin: Patient drug information";
var content_f32_34_33318=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Isotretinoin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     see \"Isotretinoin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/33/19991?source=see_link\">",
"     see \"Isotretinoin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Absorica&trade;;",
"     </li>",
"     <li>",
"      Amnesteem&reg;;",
"     </li>",
"     <li>",
"      Claravis&trade;;",
"     </li>",
"     <li>",
"      Myorisan&trade;;",
"     </li>",
"     <li>",
"      Sotret&reg;;",
"     </li>",
"     <li>",
"      Zenatane&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accutane&reg;;",
"     </li>",
"     <li>",
"      Clarus&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Your doctor will talk about the bad effects before starting you on this drug. Use 2 helpful kinds of birth control 1 month before starting this drug and for 1 month after care ends. Pregnancy tests will be done to show that you are NOT pregnant before starting and while taking this drug. If you get pregnant while taking this drug, call your doctor right away. If you know all the facts and can follow how to take this drug you must sign a patient fact/consent form. Do not sign the form and do not take this drug if you do not know everything on the form.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is only for patients in the iPLEDGE program.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702338",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to isotretinoin, vitamin A, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are of childbearing age, but are not using 2 kinds of birth control or if you are planning to get pregnant during your care or within 6 months after care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not donate blood while using this drug and for 1 month after stopping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697159",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an eating problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of vitamin A.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cosmetic skin care for at least 6 months after stopping drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, talk with your doctor about chance of pregnancy when taking this drug. You will also get a written paper talking about the bad effects if you get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697806",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You must have 2 pregnancy tests that show you are not pregnant. You will need a pregnancy test every month in order to get more drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697767",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust 1 month before care begins, during care, and for at least 1 month after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use birth control pills that have a low dose of progesterone. They may not work well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed for 1 month after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mental problems such as low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697992",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lowered night eyesight. Use care when driving or doing other tasks that call for clear eyesight. Keep work space well lit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mean actions or thoughts of fighting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will get a month's supply of this drug at a time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2860099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A liquid may be made if you cannot swallow capsules.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take 2 pregnancy tests before starting this drug and monthly while using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3803927",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Absorbica&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10777 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33318=[""].join("\n");
var outline_f32_34_33318=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185177\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185178\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028667\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028669\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028668\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028673\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028674\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028676\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028671\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028672\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028677\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028678\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=related_link\">",
"      Isotretinoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/33/19991?source=related_link\">",
"      Isotretinoin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_34_33319="Cherry angiomas";
var content_f32_34_33319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54605%7EOBGYN%2F63468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54605%7EOBGYN%2F63468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cherry angiomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple red and violaceous papules are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cherry angioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33319=[""].join("\n");
var outline_f32_34_33319=null;
var title_f32_34_33320="Thyroid hormone synthesis and physiology";
var content_f32_34_33320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thyroid hormone synthesis and physiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/34/33320/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33320/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/34/33320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33320/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/34/33320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33320/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/34/33320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormones are critical determinants of brain and somatic development in infants and of metabolic activity in adults; they also affect the function of virtually every organ system. Thyroid hormones must be constantly available to perform these functions. To maintain their availability there are large stores of thyroid hormone in the circulation and in the thyroid gland. Furthermore, thyroid hormone biosynthesis and secretion are maintained within narrow limits by a regulatory mechanism that is very sensitive to small changes in circulating hormone concentrations.",
"   </p>",
"   <p>",
"    The processes of thyroid hormone synthesis, transport, and metabolism, and the regulation of thyroid secretion will be reviewed here. The actions of thyroid hormone are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10200?source=see_link\">",
"     \"Thyroid hormone action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thyroid gland weighs 10 to 20 grams in normal adults in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/1\">",
"     1",
"    </a>",
"    ]. Thyroid volume measured by ultrasonography is slightly greater in men than women, increases with age and body weight, and decreases with increasing iodine intake [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microscopically, the thyroid is composed of spherical follicles, each composed of a single layer of follicular cells surrounding a lumen filled with colloid (mostly thyroglobulin). When stimulated, the follicular cells become columnar and the lumen is depleted of colloid; when suppressed, the follicular cells become flat and colloid accumulates in the lumen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THYROID HORMONE BIOSYNTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two biologically active thyroid hormones: thyroxine (T4) and 3,5,3'-triiodothyronine (T3) (",
"    <a class=\"graphic graphic_figure graphicRef66175 \" href=\"UTD.htm?1/36/1614\">",
"     figure 1",
"    </a>",
"    ). They are composed of a phenyl ring attached via an ether linkage to a tyrosine molecule. Both have two iodine atoms on their tyrosine (inner) ring. They differ in that T4 has two iodine atoms on its phenyl (outer) ring, whereas T3 has only one. The compound formed if an iodine atom is removed from the inner ring of T4 is 3,3',5'-triiodothyronine (reverse T3, rT3), which has no biological activity.",
"   </p>",
"   <p>",
"    T4 is solely a product of the thyroid gland, whereas T3 is a product of the thyroid and of many other tissues, in which it is produced by deiodination of T4. The thyroid gland contains large quantities of T4 and T3 incorporated in thyroglobulin, the protein within which the hormones are both synthesized and stored. Being stored in this way, T4 and T3 can be secreted more quickly than if they had to be synthesized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Iodine economy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine is essential for normal thyroid function, and it can be obtained only by consumption of foods that contain it or to which it is added.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foods rich in iodine include seafood, seaweed, kelp, dairy products, and some vegetables. Sea salt contains some iodine, and iodized salt is widely available (iodized salt in the US contains 45 to 80",
"      <span class=\"nowrap\">",
"       mcg/g).",
"      </span>",
"      Salt iodination is legally mandated in many countries (although not in the US). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=see_link\">",
"       \"Iodine-induced thyroid dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dietary iodine is absorbed as iodide and rapidly distributed in the extracellular fluid, which also contains iodide released from the thyroid and by extrathyroidal deiodination of the iodothyronines. Iodide leaves this pool by transport into the thyroid and excretion into the urine.",
"     </li>",
"     <li>",
"      The recommended daily iodine intake (Food and Nutrition Council, Institute of Medicine) is: infants 0 to 6 months, 110 mcg; infants 7 to 12 months, 130 mcg; children 1 to 8 years, 90 mcg; children 9 to 13 years, 120 mcg; adolescents and adults, 150 mcg; pregnant women, 220 mcg; lactating women, 290 mcg.",
"     </li>",
"     <li>",
"      Iodine deficiency is defined by urinary iodine excretion, as follows: mild iodine deficiency, 50 to 99",
"      <span class=\"nowrap\">",
"       mcg/L;",
"      </span>",
"      moderate iodine deficiency, 20 to 49",
"      <span class=\"nowrap\">",
"       mcg/L;",
"      </span>",
"      and severe iodine deficiency, &lt;20",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      (urinary values are approximately 70 to 80 percent of intake). Severe iodine deficiency in fetuses and infants results in severe mental and growth retardation, and even mild iodine deficiency is associated with thyroid enlargement and learning disabilities in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=see_link\">",
"       \"Iodine deficiency disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thyroid hormones are synthesized in the thyroid gland via the following steps (",
"    <a class=\"graphic graphic_figure graphicRef76931 \" href=\"UTD.htm?26/29/27088\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thyroid iodide transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodide is transported into thyroid follicular cells against a chemical and electrical gradient. Iodide transport is linked to transport of sodium, is energy-dependent and saturable, and requires oxidative metabolism. The sodium iodine transporter is an intrinsic transmembrane protein located on the basolateral membrane of the thyroid follicular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/4\">",
"     4",
"    </a>",
"    ]. Other ions such as perchlorate and pertechnetate also are transported into the thyroid by the same mechanism and, therefore, are competitive inhibitors of iodide transport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tyrosyl iodination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In thyroid follicular cells, iodide rapidly diffuses to the apical surface of the cells, where it is transported by pendrin, a membrane iodide-chloride transporter, to exocytotic vesicles fused with the apical cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/4\">",
"     4",
"    </a>",
"    ]. In these vesicles the iodide is rapidly oxidized and covalently bound (organified) to a few of the tyrosyl residues of thyroglobulin. The oxidation of iodide is catalyzed by thyroid peroxidase in a reaction that requires",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . This enzyme catalyzes iodination of about 10 percent of the tyrosine residues of thyroglobulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coupling of iodotyrosyl residues of thyroglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;T4 is formed by coupling of two diiodotyrosine residues and T3 by coupling of one monoiodotyrosine and one diiodotyrosine within a thyroglobulin molecule. These reactions also are catalyzed by thyroid peroxidase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Thyroglobulin synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroglobulin is a 660 kilodalton (kd) glycoprotein composed of two identical noncovalently linked subunits. It is found mostly in the lumen of thyroid follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/5\">",
"     5",
"    </a>",
"    ]. It is synthesized and glycosylated in the rough endoplasmic reticulum, and then incorporated into exocytotic vesicles that fuse with the apical cell membrane. Only then are tyrosine residues iodinated and coupled to form T4 and T3.",
"   </p>",
"   <p>",
"    The coupling process is not random. T4 and T3 are formed in regions of the thyroglobulin molecule with unique amino-acid sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/6\">",
"     6",
"    </a>",
"    ]. Normal thyroglobulin contains about six molecules of monoiodotyrosine, four of diiodotyrosine, two of T4, and 0.2 of T3 per molecule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Endocytosis of colloid and hormone release",
"    </span>",
"    &nbsp;&mdash;&nbsp;To liberate T4 and T3, thyroglobulin is resorbed into the thyroid follicular cells in the form of colloid droplets. The droplets fuse with lysosomes to form phagolysosomes, in which the thyroglobulin is hydrolyzed to T4, T3, and its other constituent amino acids, and some T4 is converted to T3. The hormones are then secreted into the extracellular fluid and enter the circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recycling of iodide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The iodotyrosines liberated from thyroglobulin are deiodinated by iodotyrosine deiodinase. Most of the iodide is then recycled for thyroid hormone synthesis. Homozygous mutations in DEHAL1, the gene that encodes iodotyrosine deiodinase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/7\">",
"     7",
"    </a>",
"    ], results in iodotyrosine deiodinase deficiency with hereditary and sometimes severe hypothyroidism and goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and detection of congenital hypothyroidism\", section on 'Disorders of thyroid hormone synthesis and secretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thyroglobulin secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 100 mcg of thyroglobulin is released from the thyroid each day. This is a tiny fraction of the 25 mg that must be hydrolyzed to yield the 100 mcg (130 nmoles) of T4 that is secreted each day [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Extrathyroidal T3 production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of the T3 produced is formed by 5'-deiodination (outer-ring deiodination) of T4 in extrathyroidal tissue. This reaction is catalyzed by two T4-5'-deiodinases (type I and type II), which are, respectively, plasma membrane and microsomal enzymes that require reduced sulfhydryl groups as a cofactor. The liver and kidney contain abundant deiodinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These organs are the major sources of serum T3, but some T3 is produced in most if not all tissues.",
"   </p>",
"   <p>",
"    The two types of T4-5'-deiodinase (types I and II) are distinguished by their location, biochemical properties, and responses to physiologic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I T4-5'-deiodinase is the predominant deiodinating enzyme in the liver, kidney, and thyroid. It has a high Km for T4, is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"       propylthiouracil",
"      </a>",
"      (PTU)-sensitive, and deiodinates in the following order: rT3&gt;T4&gt;T3.",
"     </li>",
"     <li>",
"      Type II T4-5'-deiodinase is the predominant deiodinating enzyme in muscle, brain, pituitary, skin, and placenta. It has a low Km for T4, is not inhibited by PTU, and deiodinates T4&gt;rT3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, in normal subjects, about 65 percent of the extrathyroidally produced T3 in serum is probably contributed by type II deiodinase and 35 percent by type I deiodinase. The proportion contributed by the type II enzyme is higher in hypothyroidism and lower in hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of polymorphisms in the deiodinase genes may ultimately prove to have clinical importance. For example, a single nucleotide polymorphism in the type I deiodinase (rs2235544) appears to increase deiodinase function, resulting in higher ratios of free",
"    <span class=\"nowrap\">",
"     T3/free",
"    </span>",
"    T4 in patients, including those taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/12\">",
"     12",
"    </a>",
"    ]. A polymorphism in the type 2 deiodinase (rs225014) may be associated with compromised psychological well-being in treated hypothyroid patients, and a favorable response to combined therapy with levothyroxine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/51/1846?source=see_link\">",
"     liothyronine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hypothyroidism\", section on 'Combination T4 and T3 therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reverse T3 is produced at extrathyroidal sites by 5-deiodination (inner ring deiodination) of T4 (type III T4-5-deiodinase). This enzyme is widely distributed throughout the body, and its properties are very similar to those of type I T4-5'-deiodinase.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3108406\">",
"    <span class=\"h2\">",
"     Selenium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deiodinases are selenoproteins, and the thyroid has more",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    per gram of tissue than any other organ. The effects of selenium deficiency on normal thyroid function are not well described; however, selenium deficiency has been shown to exacerbate both autoimmune thyroid disease and endemic cretinism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     THYROID HORMONE METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are major differences in the production and metabolism of T4 and T3, both quantitatively and qualitatively:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Thyroxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production rate of T4 is 80 to 100 mcg (100 to 130 nmoles) per day, all of which is produced in the thyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/15\">",
"     15",
"    </a>",
"    ]. The extrathyroidal pool of T4 contains 800 to 1000 mcg (1000 to 1300 nmoles), most of which is extracellular.",
"   </p>",
"   <p>",
"    T4 is degraded at a rate of about 10 percent per day. Approximately 80 percent is deiodinated, 40 percent to form T3 and 40 percent to form rT3. The remaining 20 percent is conjugated with glucuronide and sulfate, deaminated and decarboxylated to form tetraiodothyroacetic acid (tetrac), or cleaved between the two rings [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deiodination of T4 to T3 leads to increased biologic activity, but the other metabolites of T4 are biologically inactive. The conversion of T4 to T3 in extrathyroidal tissues is regulated (see below), so that production of T3 may change independently of changes in pituitary-thyroid function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Triiodothyronine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most T3 (80 percent) is produced by extrathyroidal deiodination of T4 and the rest by the thyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/15\">",
"     15",
"    </a>",
"    ]. The total production rate is 30 to 40 mcg (45 to 60 nmoles) per day. The extrathyroidal T3 pool contains about 50 mcg (75 nmoles), most of which is intracellular. T3 is degraded, mostly by deiodination, much more rapidly than T4 (about 75 percent per day).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reverse triiodothyronine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production rate of rT3 is 30 to 40 mcg (45 to 60 nmoles) daily, nearly all by extrathyroidal deiodination of T4 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/15\">",
"     15",
"    </a>",
"    ]. rT3 is degraded even more rapidly than is T3, mostly by deiodination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SERUM BINDING PROTEINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 99.95 percent of the T4 and 99.5 percent of the T3 in serum are bound to several serum proteins, thyroxine-binding globulin (TBG), transthyretin (TTR, formerly called thyroxine-binding prealbumin [TBPA]), albumin, and lipoproteins (",
"    <a class=\"graphic graphic_figure graphicRef51862 \" href=\"UTD.htm?3/52/3919\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For T4, approximately 75 percent is bound to TBG, 10 percent to TTR, 12 percent to albumin, and 3 percent to lipoproteins. Approximately 0.02 percent, or 2",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (25",
"      <span class=\"nowrap\">",
"       pmol/L),",
"      </span>",
"      of the T4 in serum is free.",
"     </li>",
"     <li>",
"      For T3, approximately 80 percent is bound to TBG, 5 percent to TTR, and 15 percent to albumin and lipoproteins. Approximately 0.5 percent, or 0.4",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (6",
"      <span class=\"nowrap\">",
"       pmol/L),",
"      </span>",
"      is free.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because nearly all of the T4 and T3 in serum is bound, changes in the serum concentrations of binding proteins, especially TBG, have a large effect on serum total T4 and T3 concentrations and the fractional metabolism of T4 and T3. They do not, however, alter free hormone concentrations or the absolute rates of metabolism of T4 and T3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=see_link\">",
"     \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General functions",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is the serum",
"    <strong>",
"     free",
"    </strong>",
"    T4 and T3 concentrations that determine the hormones' biological activity. The binding proteins serve to maintain the serum free T4 and T3 concentrations within narrow limits, yet ensure that T4 and T3 are immediately and continuously available to tissues. These proteins, therefore, have both storage and buffer functions. The storage function also facilitates uniform distribution of T4 and T3 within tissues, particularly large solid organs [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the longer term, if thyroid secretion ceases, the T4 stored in serum serves to delay the onset of hypothyroidism. In contrast, the supply would be exhausted within hours if only free T4 were available. The binding proteins also protect tissues from sudden increases in thyroid secretion or extrathyroidal T3 production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Thyroxine-binding globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;TBG is a 54-kd glycoprotein synthesized in the liver that has one binding site for T4. The affinity of TBG for T4 is very high; that for T3 is lower [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The serum TBG concentration in normal subjects is about 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.27",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    an amount capable of binding about 20 mcg of T4 (26 nmoles). Only about one-third of the TBG in serum normally contains T4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Transthyretin",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTR is a 55-kd tetrameric protein composed of four identical subunits that is synthesized in the liver. Each TTR molecule has two T4 binding sites; however, occupation of one site decreases the affinity of the second site for T4. The affinity of TTR for T4 (and T3) is less than that of TBG [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The serum TTR concentration is about 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.6",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    an amount that can bind up to 200 mcg of T4 (260 nmoles).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Albumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Albumin has one strong and several weaker binding sites for T4. There are four T4-binding albumin isoforms, with varying affinity for T4 and T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Because only about 12 percent of the T4 in serum is bound to albumin, changes in serum albumin concentrations have little effect on serum T4 concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Lipoproteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoproteins, primarily the apoprotein A-I component of high-density lipoproteins, bind a small amount of the T4 and T3 in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CELLULAR HORMONE ENTRY AND BINDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum free T4 and T3 are available for cellular uptake at any instant in time. In addition, T4 and T3 dissociate from the binding proteins so rapidly that more free T4 and T3 can become available almost instantaneously. T4 and T3 enter the cells of most organs by carrier-mediated transport and perhaps also by diffusion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T3 is also available to cells because it is produced from T4 within them. Some of the locally produced T3 must leave the cells, as evidenced by the observation that serum free (and total) T3 concentrations are normal in hypothyroid patients taking T4 in doses that raise their serum T4 concentrations to normal. However, some of the T3 does not leave, and local production of T3 provides much of the T3 that is bound to T3-nuclear receptors in many tissues. Overall, approximately 90 percent of the extrathyroidal T3 pool of 50 mcg (75 nmoles) is intracellular.",
"   </p>",
"   <p>",
"    The fraction of T3 that is produced locally from T4 and the contribution of locally produced T3 to the amount of T3 bound to its receptors vary substantially from tissue to tissue. In rats, as an example, locally produced T3 accounts for about 20 percent of the nuclear T3 in the liver, 50 percent in the pituitary, 80 percent in the cerebral cortex, and less than 10 percent in other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     T3-nuclear receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclear receptors mediate most if not all of the physiologic actions of thyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/21\">",
"     21",
"    </a>",
"    ]. Cytosolic T3 diffuses or is transported into nuclei, and then binds to the chromatin-localized receptors. Some characteristics of the receptors are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Affinity for T4 and T3 &mdash; The nuclear receptors bind T3 much more avidly than T4, and in vivo virtually all of the nuclear-bound hormone is T3. T4 is therefore largely a prohormone, with little if any intrinsic biologic activity.",
"     </li>",
"     <li>",
"      Types of receptors &mdash; There are two T3-nuclear receptors, alpha and beta, both of which are linear proteins (",
"      <a class=\"graphic graphic_figure graphicRef70770 \" href=\"UTD.htm?36/4/36928\">",
"       figure 4",
"      </a>",
"      ). The mRNAs for each receptor can be spliced in several ways, so that there are at least three forms of alpha receptors and two forms of beta receptors. The receptors differ in the structure of their amino- and carboxyl-terminal regions, but the DNA- and T3-binding regions are highly conserved, and each receptor binds to DNA in the absence of T3.",
"     </li>",
"     <li>",
"      Tissue distribution of the receptors &mdash; Beta-1 and beta-2 receptors are concentrated, respectively, in brain, heart, liver, and kidney and in pituitary and hypothalamic tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variability in tissue action &mdash; There is a variable tissue response to occupation of the nuclear receptors. In the pituitary and heart, there is a linear correlation between increasing occupancy of nuclear sites by T3 and the response, while in other tissues increasing receptor occupancy results in nonlinear, amplified responses. As an example of the latter, an increase in T3-receptor occupancy from 50 to 100 percent in the liver results in a 10-fold increase in the rate of synthesis of some enzymes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences can be explained by the diversity of the T3-nuclear receptors, the variations in their distribution among different tissues, the fact that receptors containing T3 and not containing T3 are biologically active, and variations in the tissue content of other transcription-regulating factors.",
"   </p>",
"   <p>",
"    Those tissues most responsive to T3, such as the pituitary and liver, contain more T3-nuclear receptors than do less responsive tissues, such as the spleen and testes. Furthermore, T3 regulates the production of the mRNAs for the different forms of the nuclear receptor in some tissues. In animals, hepatic T3-nuclear receptor content is reduced by starvation, diabetes, uremia, and partial hepatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Such changes, if they occurred in humans, would limit the impact of T3 in patients with nonthyroidal illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     REGULATION OF THYROID HORMONE PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone production is regulated in two ways (",
"    <a class=\"graphic graphic_figure graphicRef75399 \" href=\"UTD.htm?10/24/10629\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regulation of thyroidal biosynthesis and secretion of T4 and T3 by thyrotropin (thyroid-stimulating hormone, TSH). The secretion of TSH is inhibited by T4 and T3 and is stimulated by thyrotropin-releasing hormone (TRH).",
"     </li>",
"     <li>",
"      Regulation of extrathyroidal conversion of T4 to T3 by nutritional, hormonal, and illness-related factors. The effect of these factors differs in different tissues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first mechanism provides a very sensitive defense against alterations in thyroid secretion, and the second provides for rapid changes in tissue thyroid hormone availability in response to nonthyroidal illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Thyrotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSH is a 28-kd glycoprotein that is synthesized and secreted by the thyrotrophs of the anterior pituitary. It is composed of noncovalently bound alpha and beta subunits, and contains about 15 percent carbohydrate [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/24\">",
"     24",
"    </a>",
"    ]. The alpha subunit is the same as that of luteinizing hormone, follicle-stimulating hormone, and chorionic gonadotropin. In contrast, the beta subunit is unique and therefore determines the hormone's biologic specificity.",
"   </p>",
"   <p>",
"    The TSH secretion rate in normal subjects ranges from 75 to 150",
"    <span class=\"nowrap\">",
"     mU/day",
"    </span>",
"    (15 to 30",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    0.5 to 1",
"    <span class=\"nowrap\">",
"     nmol/day).",
"    </span>",
"    TSH secretion is pulsatile, and serum TSH concentrations are 50 to 100 percent higher in the late evening than during the day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Thyroid hormone regulation of TSH secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSH secretion is inhibited by very small increases in serum T4 and T3 concentrations, and it increases in response to very small decreases in serum T4 and T3 concentrations. As a result of this very \"tight\" control of TSH secretion, thyroid hormone secretion is maintained within very narrow limits. An important exception is that the decrease in serum T3 concentrations that occurs in patients with nonthyroidal illness has little effect on TSH secretion, probably because serum T4 contributes more to the nuclear T3 content of the hypothalamus and pituitary than it does in many other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/9,20\">",
"     9,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T4 and T3 inhibit the synthesis and release of both TSH and TRH [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The inhibition of TSH synthesis is achieved primarily by inhibition of transcription of the TSH subunit genes.",
"   </p>",
"   <p>",
"    The rate and extent of T4- and T3-induced inhibition of TSH secretion are dependent upon the initial serum TSH concentration, the particular hormone given, and its dose. Serum TSH concentrations decline within hours after administration of single 400 to 500 mcg doses of T3 or T4 to hypothyroid patients; the action of lower doses is considerably slower. The maximum inhibition of TSH secretion occurs later than the peak serum T4 or T3 concentrations. In usual doses, T3 decreases serum TSH to normal in hypothyroid patients in approximately one week, but the response to T4 is slower. When given chronically, the potency of T3 as an inhibitor of TSH secretion is about three times greater than that of T4 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/27\">",
"     27",
"    </a>",
"    ]. Conversely, serum TSH concentrations become supranormal in 10 to 14 days after cessation of T4 or T3 therapy in patients with hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Thyrotropin-releasing hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;TRH is the tripeptide pyroglutamyl-histidyl-prolineamide. It is distributed throughout the hypothalamus, but its content is highest in the median eminence and paraventricular nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/29\">",
"     29",
"    </a>",
"    ]. Small amounts of TRH are found elsewhere in the central nervous system and in the pituitary gland, gastrointestinal tract, pancreatic islets, and reproductive tract. The function of TRH in these sites is unknown.",
"   </p>",
"   <p>",
"    TRH is synthesized as a 26-kd protein (proTRH) containing five copies of the molecule. It is formed from proTRH by the action of peptidases and then cyclization of the glutamine residue to form a pyroglutamyl residue [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/30\">",
"     30",
"    </a>",
"    ]. The production of proTRH mRNA and its translation in the paraventricular nuclei are increased by hypothyroidism and decreased by local or systemic injection of T4 or T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/26\">",
"     26",
"    </a>",
"    ]. TRH is metabolized very rapidly, its plasma half-life being about three minutes.",
"   </p>",
"   <p>",
"    TRH stimulates TSH secretion via receptor-mediated activation of the phospholipase C-phosphoinositide pathway, which stimulates mobilization of calcium from intracellular storage sites. Chronic TRH stimulation also increases the synthesis and glycosylation of TSH; the latter action increases the biologic activity of TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/24\">",
"     24",
"    </a>",
"    ]. TRH secretion is probably pulsatile, accounting for pulsatile TSH secretion. Hypothyroidism ensues when TRH is absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physiologic role of TRH is to determine the set-point of thyroid hormone regulation of TSH secretion. In animals or humans with hypothalamic lesions, thyroidectomy results in smaller increases in TSH secretion and less T4 and T3 is needed to inhibit TSH secretion than in normal subjects or animals.",
"   </p>",
"   <p>",
"    Exogenous administration of TRH causes a dose-dependent increase in serum TSH concentrations in normal subjects. The response is increased in hypothyroid patients and decreased in hyperthyroid patients. Exogenous TRH administration also stimulates prolactin release in normal subjects and most patients with hyperprolactinemia, and it stimulates growth hormone secretion in normal elderly subjects and patients with acromegaly, chronic liver disease, and diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other factors altering TSH secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that affect TSH secretion include somatostatin, dopamine, and glucocorticoids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infusions of somatostatin and its long-acting analog",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      reduce serum TSH concentrations, but not as much as they reduce growth hormone secretion; patients receiving long-term treatment with octreotide do not become hypothyroid [",
"      <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/31\">",
"       31",
"      </a>",
"      ]. In animals with hypothalamic lesions that reduce somatostatin content, TSH secretion is increased, suggesting that somatostatin may be a physiologically important inhibitor of TSH secretion.",
"     </li>",
"     <li>",
"      Infusions of dopamine, in doses of 1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min or more, cause a rapid decrease in serum TSH concentrations; thus, serum TSH concentrations are often low in intensive care unit patients receiving dopamine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=see_link\">",
"       \"Drug interactions with thyroid hormones\"",
"      </a>",
"      .) Conversely, serum TSH concentrations rise after the administration of dopamine antagonists such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      . These actions are exerted on the pituitary, not the hypothalamus [",
"      <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/32\">",
"       32",
"      </a>",
"      ]. Like somatostatin, dopamine may be a physiologically important inhibitor of TSH secretion.",
"     </li>",
"     <li>",
"      Glucocorticoids also inhibit TSH secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/33\">",
"       33",
"      </a>",
"      ]. They mostly decrease pulsatile TSH secretion, indicating that they inhibit TRH secretion. However, serum TSH responses to exogenous TRH are also decreased, suggesting a direct effect on the pituitary. In contrast, decreases in cortisol production result in a transient increase in serum TSH concentrations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall impact of the inhibitory actions of somatostatin, dopamine, and glucocorticoids on TSH secretion is probably small. While increases in endogenous dopamine, somatostatin, or glucocorticoid secretion may transiently decrease TSH secretion, sustained increases in their production do not lead to sustained decreases in TSH secretion (and hypothyroidism). Once serum T4 and T3 concentrations fall, the ensuing stimulation of TSH secretion overcomes the inhibition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Mechanism of action of TSH",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSH stimulates every step in thyroid hormone synthesis and secretion by the thyroid (",
"    <a class=\"graphic graphic_figure graphicRef76931 \" href=\"UTD.htm?26/29/27088\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/3,34\">",
"     3,34",
"    </a>",
"    ]. It also stimulates intermediary metabolism and the expression of many genes in thyroid tissue, and causes thyroid hyperplasia and hypertrophy.",
"   </p>",
"   <p>",
"    The actions of TSH are initiated by its binding to specific plasma membrane receptors. The receptor is an 85-kd glycoprotein with an extracellular domain of approximately 400 amino acids, seven transmembrane domains of about 250 amino acids, and an intracytoplasmic domain of about 100 amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/34\">",
"     34",
"    </a>",
"    ]. The binding of TSH to its receptors activates adenylyl cyclase, increasing cyclic AMP formation, which then activates several protein kinases. How these steps are linked to the specific steps of thyroid hormone synthesis and secretion or to other thyroid metabolic processes is not known. TSH also stimulates phospholipase C activity in thyroid tissue, via the same receptor, thereby increasing phosphoinositide turnover, intracellular calcium ion concentrations, and protein kinase C activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other thyroid-stimulating substances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that may be involved in thyroid growth (goiter formation) include insulin-like growth factor I and epidermal growth factor. Thyroid cells produce and have receptors for these substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Regulation of extrathyroidal T3 production",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of the extrathyroidal T4-5'-deiodinases that catalyze the conversion of T4 to T3 is altered by many factors.",
"   </p>",
"   <p>",
"    The activity of type I T4-5'-deiodinase, the enzyme that predominates in liver and kidney, is decreased in tissues from fetal animals and animals that are starved, hypothyroid, diabetic, uremic, or have other nonthyroidal illnesses (",
"    <a class=\"graphic graphic_table graphicRef58529 \" href=\"UTD.htm?38/63/39931\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/9,10,20,22,35\">",
"     9,10,20,22,35",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     Propylthiouracil",
"    </a>",
"    , glucocorticoids, beta blockers, and various iodothyronine analogues, notably rT3, also decrease the activity of this enzyme. On the other hand, type I T4-5'-deiodinase activity is increased by hyperthyroidism, glucose plus insulin, and a high caloric intake [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biochemical mechanisms that might cause alterations in tissue T4-5'-deiodinase activity include alterations in substrate (T4) production, transport of T4 into cells, intracellular distribution of T4, enzyme activity or mass, and cofactor availability. The drugs that reduce T4-5'-deiodinase activity bind to the enzyme, whereas starvation may decrease hepatic T3 production by decreasing T4 uptake into the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/37\">",
"     37",
"    </a>",
"    ]. In other situations, alterations of enzyme mass or activity are the likely cause(s) of decreased T3 production, but the specific nutritional, hormonal, or toxic factors or cytokines that cause these changes are not known.",
"   </p>",
"   <p>",
"    In the laboratory rodent, the regulation of the type II T4-5'-deiodinase that predominates in brain, pituitary, and muscle is different (",
"    <a class=\"graphic graphic_table graphicRef58529 \" href=\"UTD.htm?38/63/39931\">",
"     table 1",
"    </a>",
"    ). Its activity is increased by thyroid deficiency, little affected by nutritional deficiency and PTU, and decreased by hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/9,10,20,35,38\">",
"     9,10,20,35,38",
"    </a>",
"    ]. Such regulation serves to reduce the impact of systemic thyroid deficiency in these tissues by increasing the availability of T3 for maintenance of neural growth and function and pituitary function.",
"   </p>",
"   <p>",
"    In humans, however, hypothyroidism did not modulate the expression of the type II T4-5'-deiodinase in skeletal muscle biopsies, suggesting there may be significant differences in physiology between rodents and humans [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33320/abstract/39\">",
"     39",
"    </a>",
"    ]. The increase in pituitary T4-5'-deiodinase activity that occurs in thyroid deficiency and the decrease that occurs in rodents with thyroid hormone excess probably do not include the thyrotrophs, because alterations in T3 production in these cells would blunt the changes in TSH secretion needed to defend against changes in thyroidal T4 and T3 secretion.",
"   </p>",
"   <p>",
"    Overall, these findings indicate that the production of T3 in different tissues is regulated in different ways, and that changes in thyroidal or extrathyroidal thyroid hormone production, as manifested by their circulating concentrations, are not the only and, perhaps, not the major, determinants of intracellular T3 availability. Local regulation of T3 production may be particularly important in reducing the impact of thyroid deficiency in tissues such as the brain and pituitary, and this local regulation undoubtedly leads to differences in T3 content in different tissues in patients with nonthyroidal illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3108421\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroxine (T4) is solely a product of the thyroid gland, whereas most 3,5,3'-triiodothyronine (T3) is produced in peripheral organs from deiodination of T4. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Thyroid hormone biosynthesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T4, and T3 of thyroidal origin, is synthesized by iodination and coupling of tyrosyl residues within thyroglobulin, which is stored in the colloid space (",
"      <a class=\"graphic graphic_figure graphicRef76931 \" href=\"UTD.htm?26/29/27088\">",
"       figure 2",
"      </a>",
"      ). Endocytosis of colloid and release of thyroid hormone occurs in response to TSH. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Thyroid hormone biosynthesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both hormones are bound to TBG, transthyretin, and albumin. Bound hormone represents a circulating storage pool, while unbound (free) hormone is available for uptake into tissues. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Serum binding proteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T3 occupies specific nuclear receptors, mediating the physiologic action of thyroid hormone. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'T3-nuclear receptors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/1\">",
"      Pankow BG, Michalak J, McGee MK. Adult human thyroid weight. Health Phys 1985; 49:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/2\">",
"      Heged&uuml;s L. Thyroid size determined by ultrasound. Influence of physiological factors and non-thyroidal disease. Dan Med Bull 1990; 37:249.",
"     </a>",
"    </li>",
"    <li>",
"     Kopp P. Thyroid hormone synthesis. In: The Thyroid: Fundamental and Clinical Text, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.52.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/4\">",
"      Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 2000; 10:321.",
"     </a>",
"    </li>",
"    <li>",
"     Arvan P, Di Jeso B. Thyroglobulin structure, function, and biosynthesis. In: The Thyroid: Fundamental and Clinical Text, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/6\">",
"      Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion. (First of two parts). N Engl J Med 1979; 301:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/7\">",
"      Moreno JC. Identification of novel genes involved in congenital hypothyroidism using serial analysis of gene expression. Horm Res 2003; 60 Suppl 3:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/8\">",
"      Moreno JC, Klootwijk W, van Toor H, et al. Mutations in the iodotyrosine deiodinase gene and hypothyroidism. N Engl J Med 2008; 358:1811.",
"     </a>",
"    </li>",
"    <li>",
"     Bianco AC, Larsen PR. Intracellular pathways of iodothyronine metabolism. In: The Thyroid: Fundamental and Clinical Text, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/10\">",
"      Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006; 116:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/11\">",
"      Maia AL, Kim BW, Huang SA, et al. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 2005; 115:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/12\">",
"      Panicker V, Cluett C, Shields B, et al. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab 2008; 93:3075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/13\">",
"      Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009; 94:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/14\">",
"      Duntas LH. Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab 2010; 95:5180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/15\">",
"      Engler D, Burger AG. The deiodination of the iodothyronines and of their derivatives in man. Endocr Rev 1984; 5:151.",
"     </a>",
"    </li>",
"    <li>",
"     Benvenga S. Thyroid hormone transport proteins and the physiology of hormone binding. In: The Thyroid: Fundamental and Clinical Text, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.97.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/17\">",
"      Bartalena L. Recent achievements in studies on thyroid hormone-binding proteins. Endocr Rev 1990; 11:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/18\">",
"      Mendel CM, Weisiger RA, Jones AL, Cavalieri RR. Thyroid hormone-binding proteins in plasma facilitate uniform distribution of thyroxine within tissues: a perfused rat liver study. Endocrinology 1987; 120:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/19\">",
"      Hennemann G, Docter R, Friesema EC, et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev 2001; 22:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/20\">",
"      Larsen PR, Silva JE, Kaplan MM. Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr Rev 1981; 2:87.",
"     </a>",
"    </li>",
"    <li>",
"     Yen PM. Genomic and nongenomic actions of thyroid hormones. In: The Thyroid: Fundamental and Clinical Text, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/22\">",
"      Lim VS, Passo C, Murata Y, et al. Reduced triiodothyronine content in liver but not pituitary of the uremic rat model: demonstration of changes compatible with thyroid hormone deficiency in liver only. Endocrinology 1984; 114:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/23\">",
"      Jolin T. Diabetes decreases liver and kidney nuclear 3,5,3'-triiodothyronine receptors in rats. Endocrinology 1987; 120:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/24\">",
"      Magner JA. Thyroid-stimulating hormone: biosynthesis, cell biology, and bioactivity. Endocr Rev 1990; 11:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/25\">",
"      Shupnik MA, Ridgway EC, Chin WW. Molecular biology of thyrotropin. Endocr Rev 1989; 10:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/26\">",
"      Dyess EM, Segerson TP, Liposits Z, et al. Triiodothyronine exerts direct cell-specific regulation of thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus. Endocrinology 1988; 123:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/27\">",
"      Sawin CT, Hershman JM, Chopra IJ. The comparative effect of T4 and T3 on the TSH response to TRH in young adult men. J Clin Endocrinol Metab 1977; 44:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/28\">",
"      Leboeuf R, Perron P, Carpentier AC, et al. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clin Endocrinol (Oxf) 2007; 67:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/29\">",
"      Jackson IM. Thyrotropin-releasing hormone. N Engl J Med 1982; 306:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/30\">",
"      Wu P, Lechan RM, Jackson IM. Identification and characterization of thyrotropin-releasing hormone precursor peptides in rat brain. Endocrinology 1987; 121:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/31\">",
"      Williams TC, Kelijman M, Crelin WC, et al. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. J Clin Endocrinol Metab 1988; 66:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/32\">",
"      Brabant G, Prank K, Hoang-Vu C, et al. Hypothalamic regulation of pulsatile thyrotopin secretion. J Clin Endocrinol Metab 1991; 72:145.",
"     </a>",
"    </li>",
"    <li>",
"     Hollenberg AN. Regulation of thyrotropin secretion. In: The Thyroid: Fundamental and Clinical Text, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/34\">",
"      Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/35\">",
"      Kaplan MM, Utiger RD. Iodothyronine metabolism in rat liver homogenates. J Clin Invest 1978; 61:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/36\">",
"      Danforth E Jr, Horton ES, O'Connell M, et al. Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest 1979; 64:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/37\">",
"      van der Heyden JT, Docter R, van Toor H, et al. Effects of caloric deprivation on thyroid hormone tissue uptake and generation of low-T3 syndrome. Am J Physiol 1986; 251:E156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/38\">",
"      Silva JE, Leonard JL. Regulation of rat cerebrocortical and adenohypophyseal type II 5'-deiodinase by thyroxine, triiodothyronine, and reverse triiodothyronine. Endocrinology 1985; 116:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33320/abstract/39\">",
"      Heemstra KA, Soeters MR, Fliers E, et al. Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. J Clin Endocrinol Metab 2009; 94:2144.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7837 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33320=[""].join("\n");
var outline_f32_34_33320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3108421\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THYROID HORMONE BIOSYNTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Iodine economy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thyroid iodide transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tyrosyl iodination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coupling of iodotyrosyl residues of thyroglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Thyroglobulin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Endocytosis of colloid and hormone release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recycling of iodide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thyroglobulin secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Extrathyroidal T3 production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3108406\">",
"      Selenium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      THYROID HORMONE METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Thyroxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Triiodothyronine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reverse triiodothyronine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SERUM BINDING PROTEINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General functions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Thyroxine-binding globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Transthyretin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lipoproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CELLULAR HORMONE ENTRY AND BINDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      T3-nuclear receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      REGULATION OF THYROID HORMONE PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Thyrotropin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Thyroid hormone regulation of TSH secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Thyrotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other factors altering TSH secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Mechanism of action of TSH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other thyroid-stimulating substances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Regulation of extrathyroidal T3 production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3108421\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7837|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/36/1614\" title=\"figure 1\">",
"      Thyroid hormone structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/29/27088\" title=\"figure 2\">",
"      Thyroid hormone synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/52/3919\" title=\"figure 3\">",
"      Thyroid hormones in serum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/4/36928\" title=\"figure 4\">",
"      T3 nuclear receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/24/10629\" title=\"figure 5\">",
"      Regulation thyroid hormone production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/63/39931\" title=\"table 1\">",
"      Regulation of T4 5 deiodinase",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=related_link\">",
"      Drug interactions with thyroid hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=related_link\">",
"      Iodine deficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10200?source=related_link\">",
"      Thyroid hormone action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_34_33321="Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors";
var content_f32_34_33321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/34/33321/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33321/contributors\">",
"     George D Demetri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33321/contributors\">",
"     Jeffrey Morgan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33321/contributors\">",
"     Chandrajit P Raut, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/34/33321/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33321/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33321/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/34/33321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/34/33321/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/34/33321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract are divided into two groups. The most common group consists of neoplasms that are collectively referred to as gastrointestinal stromal tumors (GISTs). They are most often located in the stomach and proximal small intestine, but can occur in any portion of the alimentary tract, and occasionally in the omentum, mesentery, and peritoneum. The far less common group is comprised of a spectrum of tumors that are identical to those that might arise in the soft tissues throughout the rest of the body (ie, lipomas, liposarcomas, leiomyomas, true leiomyosarcomas, desmoid tumors, schwannomas, and peripheral nerve sheath tumors).",
"   </p>",
"   <p>",
"    The pathologic characterization of GIST as a unique form of GI sarcoma was first described in 1983, and it was later demonstrated that mutational activation of one of two proto-oncogenes, KIT or platelet-derived growth factor receptor-alpha (PDGFRA), stimulated the growth of the cancer cells. These mutations represent the molecular hallmark of GISTs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings led to the development of effective systemic therapies in the form of small molecule tyrosine kinase inhibitors (TKIs), of which the prototype is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . These agents block signaling via KIT and PDGFRA by binding to the adenosine triphosphate-binding pocket required for phosphorylation and activation of the receptor. The end result is inhibition of tumor proliferation. The effectiveness of these agents can be illustrated by the fact that following the introduction of imatinib, the median survival of patients with advanced GIST increased from approximately 20 to 60 months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success of these agents in advanced disease prompted interest in their perioperative use. This includes both preoperative or induction therapy for patients with unresectable or borderline resectable tumors, and adjuvant treatment for patients at high risk of recurrence after complete resection of a primary GIST tumor.",
"   </p>",
"   <p>",
"    This topic review will cover the perioperative use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for localized GIST tumors. The epidemiology, classification, molecular pathogenesis, diagnostic workup, and surgical treatment of localized GISTs, and the use of TKIs in patients with unresectable or metastatic disease are covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34938?source=see_link\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard of care for patients with a primary resectable GIST is surgery, aiming for a macroscopically complete resection with negative microscopic margins. Complete resection is possible in the majority of localized GISTs, but only about one-half remain recurrence-free for five or more years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34938?source=see_link\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Estimation of recurrence risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of recurrence risk following resection of a GIST is of paramount importance when selecting patients who could possibly benefit from adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Several criteria have been proposed, originally to classify the malignant potential of a GIST. Although the terms \"benign\" and \"malignant\" are no longer applied to GIST, since all are considered to have malignant potential, tumor size, mitotic rate, and site of tumor origin have gained the greatest acceptance as being predictive of the risk of recurrence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Prognostic determinants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk stratification models, such as the original NIH consensus criteria, have been proposed to distinguish prognosis in resected GIST (",
"    <a class=\"graphic graphic_table graphicRef53231 \" href=\"UTD.htm?39/42/40620\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/3\">",
"     3",
"    </a>",
"    ]. In the series of 289 patients used to construct this model, the cumulative five-year disease-specific survival rates for GISTs classified as risk level I through IV were 100, 96, 67, and 25 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Prognostic determinants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Models such as these do not take into account the location of the GIST. In general, tumors arising from the small bowel, colon, rectum, or mesentery are associated with less favorable outcomes than those arising from the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Other risk prediction models have taken location into account (",
"    <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"     table 2",
"    </a>",
"    ). As an example, largely based upon these data from the Armed Forces Institute of Pathology, which represent the largest published experience with GISTs diagnosed and treated in the modern era for which long-term clinical follow-up is available, a TNM (tumor-node-metastasis) staging system for GIST was developed by the American Joint Committee on Cancer (AJCC) and International Union Against Cancer (UICC), and published in the 2010 7th edition of the cancer staging manual (",
"    <a class=\"graphic graphic_table graphicRef51606 \" href=\"UTD.htm?8/35/8766\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/7\">",
"     7",
"    </a>",
"    ]. The T and N designations are similar for all disease sites, but there are separate stage groupings for",
"    <span class=\"nowrap\">",
"     gastric/omental,",
"    </span>",
"    and for small",
"    <span class=\"nowrap\">",
"     bowel/esophageal/colorectal/mesenteric",
"    </span>",
"    primaries. Rates of disease progression for gastric and small bowel GISTs, stratified by stage at diagnosis, are presented in the tables (",
"    <a class=\"graphic graphic_table graphicRef78594 \" href=\"UTD.htm?10/1/10268\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54480 \" href=\"UTD.htm?10/14/10476\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Tumor size, mitotic rate, and location'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not included in the TNM staging system, tumor rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/8\">",
"     8",
"    </a>",
"    ] and incomplete resection are also independent risk factors that negatively impact disease-free survival. A modification of the NIH consensus criteria for risk stratification has been proposed that incorporates both site and tumor rupture as prognostic variables [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H14297093#H14297093\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Tumor rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an alternative to the risk-classification systems that stratify patients into discrete categories, others have quantified the risk of disease recurrence after complete resection as a continuous variable though the use of a",
"    <a class=\"external\" href=\"file://www.mskcc.org/cancer-care/adult/gastrointestinal-neuroendocrine-tumors/prediction-tools\">",
"     GIST tumor nomogram",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of risk stratification schemes is to identify those patients who are at the highest risk for recurrence so that management (in particular, the use of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ) can be individualized. However, there is no clear consensus from expert groups as to what level or cutoff of recurrence risk would justify the use of adjuvant imatinib. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Summary and recommendations of expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This issue was addressed in an analysis of data from 10 different population-based published series totaling 2560 patients with completely resected GIST, none of whom received adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/8\">",
"     8",
"    </a>",
"    ]. Tumors were classified according to the NIH consensus criteria (",
"    <a class=\"graphic graphic_table graphicRef53231 \" href=\"UTD.htm?39/42/40620\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/3\">",
"     3",
"    </a>",
"    ], a modification of the NIH consensus criteria that includes site and tumor (",
"    <a class=\"graphic graphic_table graphicRef85938 \" href=\"UTD.htm?13/13/13532\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/9\">",
"     9",
"    </a>",
"    ], and the AFIP criteria (",
"    <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/4\">",
"     4",
"    </a>",
"    ]. Large tumor size, high mitotic counts, non-gastric location, presence of rupture, and male sex were all independent adverse prognostic factors. Most recurrences occurred within the first five years of follow-up, and most patients were cured by surgery alone (estimated 5, 10, and 15-year relapse-free survival [RFS] rates 71, 63, and 60 percent, respectively).",
"    <br/>",
"    <br/>",
"    A comparison of the NIH, modified NIH, and AFIP criteria showed that all appropriately predicted RFS and identified high-risk patients. The proposed, modified NIH criteria (",
"    <a class=\"graphic graphic_table graphicRef85938 \" href=\"UTD.htm?13/13/13532\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/9\">",
"     9",
"    </a>",
"    ] were best at identifying a single subgroup of patients at high risk of recurrence. With all of the different classification schemes, those patients who were identified as intermediate risk had a clinical course that was similar to the low-risk group, suggesting that only the high-risk patients would likely benefit from adjuvant therapy. &nbsp;",
"   </p>",
"   <p>",
"    These investigators also developed a novel risk stratification scheme in which tumor size and mitotic counts were assessed as continuous non-linear variables; novel prognostic contour maps were generated based upon these data plus site and tumor rupture. These maps were better than conventional models at predicting 10-year risk for GIST recurrence and would be particularly useful for discussing individual risks with patients as they are graphic and easy to explain. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Benefit of imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in the setting of advanced disease prompted interest in its use in the adjuvant setting after complete resection of a primary tumor or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Phase II trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the phase II US Intergroup trial, American College of Surgeons Oncology Group (ACOSOG) Z9000, 107 patients with a completely resected GIST &ge;10 cm in size, ruptured, hemorrhaging, or multifocal GIST (&lt;5 sites total) all received 400 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    daily for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/12\">",
"     12",
"    </a>",
"    ]. Recurrence-free survival (RFS) was the primary endpoint. In a preliminary report, at a median follow-up of four years, the one-, two-, and three-year overall survival rates were 99, 97, and 97 percent, respectively, and the corresponding rates of relapse-free survival (RFS) were 94, 73, and 61 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Phase III trials",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647861366\">",
"    <span class=\"h4\">",
"     ACOSOG Z9001",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    compared to surgery alone was shown in a subsequent phase III, double-blind multicenter ACOSOG Z9001 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/13\">",
"     13",
"    </a>",
"    ]. In this trial, 713 adults with a completely resected primary gastrointestinal GIST at least 3 cm in maximal diameter and immunohistochemically positive for KIT protein were randomly assigned to one year of adjuvant imatinib (400 mg daily) or placebo. The primary endpoint was RFS.",
"   </p>",
"   <p>",
"    The trial was stopped early when planned interim analysis disclosed that significantly fewer patients in the treated group recurred. At a median follow-up of 20 months, 30 patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    group recurred or died, versus 70 in the placebo group (8 versus 20 percent). The one-year RFS rate was 98 versus 83 percent favoring imatinib, with a hazard ratio for RFS of 0.35, 95% CI 0.22 to 0.53 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subgroup analysis revealed that RFS was significantly longer with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in all risk categories (based upon size, mitotic rate, and location in the GI tract) (",
"    <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"     table 2",
"    </a>",
"    ). As expected, in a later analysis, the absolute benefit was greatest in those with high-risk disease (relapse rate 47 versus 19 percent for placebo and imatinib, respectively); for moderate risk disease it was 14 versus 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    was well tolerated by most patients. The drug was discontinued because of adverse reactions in 16 versus 5 percent of the placebo group. The side effect profile overall was similar to that observed in other clinical trials of imatinib. There were no significant cardiac toxic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H44#H44\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Imatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No overall survival differences have emerged in favor of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in the ACOSOG Z9001 trial. Among the possible reasons are the short duration of follow-up, the limited number of relapses, and the high degree of efficacy of imatinib in relapsed disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, after the study was unblinded, all patients randomized to placebo were allowed to crossover to active treatment, thus obscuring any potential differences in overall survival between the groups.",
"   </p>",
"   <p>",
"    Based upon these findings,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    was given accelerated approval in the US in 2008 for adjuvant treatment of completely resected GISTs &ge;3 cm in size, without definitive guidance as to the optimal duration of treatment or which patients are most likely to benefit.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    was clearly effective at reducing disease recurrence in this trial, key questions remain [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Two important issues are the value of longer duration imatinib following complete resection and the definition of subsets of patients who derive the most benefit from adjuvant imatinib. Patients with GIST of more than 3 cm are a highly heterogeneous population, within which the risk of relapse and death varies considerably. Furthermore, as noted above, the risk of relapse is affected not only by size, but also by mitotic index, location of the primary site, and molecular factors. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Estimation of recurrence risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Refining the indications for adjuvant treatment remains a big task for future studies.",
"   </p>",
"   <p>",
"    Although not included in the study, the results may be relevant to the 4 percent of patients with GISTs that lack KIT overexpression, but have mutations in KIT or PDGFRA, and can respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/1\">",
"     1",
"    </a>",
"    ]. On the other hand, patients who lack detectable KIT or PDGFRA mutations or who have specific mutations that are known to be insensitive to imatinib (eg, PDGFRA exon 18 D842V) may not benefit. Whether such patients should be identified prospectively and specifically excluded from receiving adjuvant imatinib is unclear. Routine molecular testing of individual GISTs to define genotype is not performed widely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H9#H9\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Influence of mutations on response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1805370\">",
"    <span class=\"h3\">",
"     SSG XVIII trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Scandinavian Sarcoma Group (SSG) XVIII trial compared 36 versus 12 months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (400 mg daily) in 400 patients with high-risk resected GIST [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/18\">",
"     18",
"    </a>",
"    ]. High-risk was defined according to the modified consensus criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/19\">",
"     19",
"    </a>",
"    ] as having at least one of the following: tumor size &gt;10 cm, mitotic count",
"    <span class=\"nowrap\">",
"     &gt;10/50",
"    </span>",
"    high-power fields (hpf), tumor size &gt;5 cm with mitotic rate",
"    <span class=\"nowrap\">",
"     &gt;5/hpf,",
"    </span>",
"    or tumor rupture. About one-half of the enrolled patients had gastric primary tumors.",
"   </p>",
"   <p>",
"    At a median follow-up of 54 months, prolonged treatment was associated with a significant improvement in RFS, the primary endpoint (five-year RFS 66 versus 48 percent, HR 0.46, 95% CI 0.32 to 0.65) as well as overall survival (92 versus 82 percent, HR 0.45, 85% CI 0.22 to 0.89). Treatment-related adverse effects were more common with longer treatment, including periorbital edema (74 versus 59 percent), diarrhea (54 versus 44 percent), and muscle cramps (49 versus 31 percent). However, most were grade 1 or 2; the number of grade 3 or 4 events was similar in both groups. Nevertheless, twice as many patients discontinued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for reasons other than disease progression in the prolonged therapy group (26 versus 13 percent).",
"   </p>",
"   <p>",
"    These data establish at least 36 months of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    as a new standard for patients with high-risk GIST, but questions remain as to whether treatment should be continued for longer than three years. In both groups, within 6 to 12 months of discontinuing adjuvant imatinib, rates of disease recurrence were similarly increased. This finding raises questions as to whether recurrences are truly being prevented or just delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647861381\">",
"    <span class=\"h4\">",
"     Other completed trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the ACOSOG Z9001 trial and the SSG XVIII trial, both of which had RFS as the primary endpoint, the Intergroup EORTC 62024 trial, a randomization between two years of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and observation alone, has been completed and is awaiting data maturation. Overall survival is the primary end point. A single-arm phase II five-year adjuvant imatinib trial, PERSIST5, has also completed accrual; data will not be available for several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6457205\">",
"    <span class=\"h3\">",
"     Imatinib dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACOSOG Z9001 trial tested only the 400 mg daily dose in the adjuvant setting. In randomized trials, patients with advanced GIST and KIT exon 9 mutations do better with 800 mg daily doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H9#H9\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Influence of mutations on response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether doses greater than 400 mg should be used in the adjuvant setting will require prospective study. Until further information becomes available, some centers, including ours, routinely genotype patients with lower gastrointestinal GISTs who are starting adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . The vast majority of the exon 9 mutants come from small bowel GISTs, and we encourage patients who have these mutations to take 600 to 800 mg of imatinib daily rather than 400 mg daily, if tolerated. However, this practice is not widespread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11883426\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus as to what cutoff for disease recurrence should be used to select patients for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , and practice is variable. The following information informs this debate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2008, the FDA granted accelerated approved for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in the adjuvant setting for completely resected primary GIST &ge;3 cm without indicating the optimal length of therapy; labeling was updated in January 2012 to include the significantly prolonged survival seen with three years of therapy as compared to one year of adjuvant imatinib. However, whether all patients in this broad category have a high enough risk of recurrence to warrant adjuvant therapy is not established. The EMA (European Medicines Agency) has extended the licensed indications of imatinib to include adjuvant treatment of adult patients who are at \"significant risk of relapse\" after resection of a KIT-positive GIST, but does not define these subsets further.",
"     </li>",
"     <li>",
"      The SSGXVIII trial defined high risk as follows: a ruptured GIST, tumor size &gt;10 cm, mitotic rate",
"      <span class=\"nowrap\">",
"       &gt;10/50",
"      </span>",
"      HPF, or tumor size &gt;5 cm and &gt;5",
"      <span class=\"nowrap\">",
"       mitoses/HPF",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/18\">",
"       18",
"      </a>",
"      ]. The risk of recurrence in these groups is approximately one-third or higher [",
"      <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Existing consensus-based clinical practice guidelines from the National Comprehensive Cancer Network (",
"      <a class=\"external\" href=\"file://www.nccn.org/\">",
"       NCCN",
"      </a>",
"      ) suggest adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      for at least 36 months for patients with high risk GIST (tumor &gt;5 cm in size with high mitotic rate [&gt;5",
"      <span class=\"nowrap\">",
"       mitoses/50",
"      </span>",
"      HPF] or a risk of recurrence that is &gt;50 percent). &nbsp;",
"     </li>",
"     <li>",
"      Risk stratification tools are available, based upon tumor size, mitotic rate, location, and tumor rupture, and they all define a &ldquo;high-risk&rdquo; subset. The 2012 analysis of Joensuu, described above, found that all risk classification schema identified a group of patients with high-risk disease who had a significantly worse RFS than did those with intermediate-risk of low-risk disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/9\">",
"       9",
"      </a>",
"      ]. The proposed, modified NIH criteria (",
"      <a class=\"graphic graphic_table graphicRef85938 \" href=\"UTD.htm?13/13/13532\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/9\">",
"       9",
"      </a>",
"      ] were best at identifying a single subgroup of patients at high risk of recurrence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Estimation of recurrence risk'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients who were identified as intermediate risk had a clinical course that was similar to the low-risk group, suggesting that only the high-risk patients would likely benefit from adjuvant therapy. Although the concept that only high risk patients derive benefit from adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      has not been prospectively validated, based upon these data, it would seem reasonable to offer adjuvant therapy to all patients who fall into a &ldquo;high-risk&rdquo; category regardless of the risk stratification model used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEOADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the only potentially curative option for GIST. Given the high response rates to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (and potential for complete pathologic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/23\">",
"     23",
"    </a>",
"    ]) in the setting of advanced disease, there are several clinical scenarios in which neoadjuvant treatment could be considered. This includes an unresectable or borderline resectable primary tumor, a potentially resectable tumor that requires extensive organ disruption, a local recurrence of locally advanced disease, or a limited amount of potentially resectable metastatic disease. In all cases, the goal of treatment is a reduction in tumor size that may facilitate complete surgical resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increase the likelihood of organ preservation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H2#H2\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Efficacy of imatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials addressing the benefit of neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Since 2003, several case reports and small retrospective series have been published, most of which include a mix of patients with borderline resectable and unresectable primary disease, as well as metastatic and locally recurrent disease that is potentially amenable to gross resection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/24-30\">",
"     24-30",
"    </a>",
"    ]. A single phase II US Intergroup trial of neoadjuvant imatinib has been completed, and preliminary results are available [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     RTOG 0132/ACRIN 6665 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multicenter RTOG (Radiation Therapy Oncology Group)",
"    <span class=\"nowrap\">",
"     0132/ACRIN",
"    </span>",
"    (American College of Radiology Imaging Network) 6665 trial was a prospective phase II trial in which 63 patients with KIT-positive GIST, and either a resectable primary &ge;5 cm, or resectable recurrent disease received preoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    600 mg daily for 8 to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/31\">",
"     31",
"    </a>",
"    ]. Following surgery, all patients received at least two additional years of postoperative imatinib, while those with metastatic disease were treated until disease progression.",
"   </p>",
"   <p>",
"    Thirty of the 52 analyzable patients had locally advanced primaries, and 22 had locally recurrent or metastatic disease. Among the patients with localized primary disease, only two (7 percent) had an objective response to preoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (as assessed by CT scan), but stable disease was achieved in 25 (83 percent). The corresponding values for the group with metastatic disease were 5 and 91 percent, respectively.",
"   </p>",
"   <p>",
"    In the latest update at a median follow-up of 5.1 years, the estimated five-year progression-free and disease-specific survival rates for patients presenting with localized primary disease were 57 and 77 percent, respectively; the corresponding rates were 30 and 68 percent in those with recurrent or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/32\">",
"     32",
"    </a>",
"    ]. These data support the view that longer postoperative treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in patients with high-risk disease should be considered, although the optimal duration is not established. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Summary and recommendations of expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While this trial confirmed the safety of neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , it tested a relatively brief period of preoperative treatment. The available data from patients treated for advanced disease suggest that maximal radiographic response to imatinib generally occurs after three to nine months of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Retrospective series",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from retrospective series also support the benefit of initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/25-28,30,33\">",
"     25-28,30,33",
"    </a>",
"    ]. The largest experience consisted of 46 patients who underwent surgery after imatinib, 11 with a locally advanced primary tumor, and 35 with recurrent or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/25\">",
"     25",
"    </a>",
"    ]. All 11 patients who were treated for a locally advanced primary tumor (median 12 months of imatinib prior to resection, with one complete and eight partial responses as assessed by CT) successfully underwent complete surgical resection. There was one complete pathologic response. At a median follow-up of 19.7 months postresection, all 11 remained alive, ten recurrence-free.",
"   </p>",
"   <p>",
"    There were 11 partial responses among the 35 patients treated for",
"    <span class=\"nowrap\">",
"     recurrent/metastatic",
"    </span>",
"    disease, and 11 patients were able to undergo a compete resection, two with pathologic complete response. Patients with an objective partial response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (by CT) were significantly more likely to undergo a complete resection (91 versus 4 percent of those whose best response was progressive disease). All eleven of the completely resected patients remained alive at a median follow-up of 30.7 months, but six recurred at a median of 15 months, despite continued imatinib.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Response assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best method to assess response of a GIST to TKIs is controversial. PET scanning using fluorodeoxyglucose (FDG-PET) is highly sensitive for detecting tumors with a high glucose metabolism. Accumulating data support the view that very early evidence of tumor response (within days of instituting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/34\">",
"     34",
"    </a>",
"    ]) can be obtained through the use of metabolic imaging as compared to conventional CT scanning. A clinical scenario where obtaining a baseline and follow-up PET scan might prove useful is a borderline resectable GIST (or a potentially resectable tumor that requires extensive organ disruption) in which there is a narrow window for moving to alternative therapy (eg, resection or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ) if imatinib is ineffective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H3#H3\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Assessing response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A provocative trial suggests that response rates to very brief periods of neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (three to seven days), as assessed by FDG-PET and dynamic CT, are as high as 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/35\">",
"     35",
"    </a>",
"    ]. However, in this small prospective randomized phase II trial, there was no evidence of histologic cytoreduction (and therefore, no potential benefit in terms of reduced tumor bulk) from &le; 7 days of neoadjuvant imatinib, and no suggestion that intraoperative blood loss was reduced, even though blood flow to the tumor was reduced as measured by dynamic CT. Thus, the clinical benefit of very short periods of neoadjuvant imatinib (termed \"nanoneoadjuvant therapy\" [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/36\">",
"     36",
"    </a>",
"    ]) is unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Summary and recommendations of expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although randomized trials proving benefit are not available, data from retrospective series and an early report of a prospective multicenter phase II trial suggest that initial (neoadjuvant) therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    can reduce tumor bulk, and permit later resection of initially unresectable or borderline resectable disease.",
"   </p>",
"   <p>",
"    There is no consensus as to the indications for neoadjuvant therapy. Some limit this approach to patients with identifiable high-risk characteristics (size &gt;5 cm, &gt;5 mitoses per 50 hpf, anatomic location resulting in a potentially morbid resection) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/37\">",
"     37",
"    </a>",
"    ]. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    recommend initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for patients with marginally resectable tumors and for those who have potentially resectable disease but with the risk of significant morbidity. We agree with this approach. Another circumstance in which neoadjuvant treatment might be beneficial is in patients with a GIST arising in the esophagus, esophagogastric junction, duodenum, or distal rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/38\">",
"     38",
"    </a>",
"    ]. Preoperative treatment might shrink the tumor and permit a more conservative local excision to be performed rather than radical surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34938?source=see_link&amp;anchor=H2687275#H2687275\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\", section on 'Neoadjuvant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients should be managed in a center that has a strong multidisciplinary team approach. The usual schema is give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for anywhere from 3 to 12 months, with frequent imaging studies, and periodic reevaluation for surgical intervention. The decision as to how long to administer imatinib and when to operate (ie, at first resectability versus after achieving maximal response) must be individualized. For patients in whom tumor shrinkage would lessen the complexity of the surgical procedure, imatinib is often administered for up to 12 months, as long as a continued radiographic response is evident.",
"   </p>",
"   <p>",
"    A daily dose of 400 mg per day is the usual approach, although if a",
"    <em>",
"     KIT",
"    </em>",
"    exon 9 mutation is identified, dose escalation to 800 mg per day is reasonable, and is recommended in ESMO guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/39\">",
"     39",
"    </a>",
"    ]. However, routine genotyping of GISTs is not recommended in guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    , and not widely practiced. Other mutations are insensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    altogether (eg, PDGFRA exon 18 D842V mutations). If routine genotyping is not practiced, it is probably wise to check for an early response to neoadjuvant imatinib using CT, PET, or contrast-enhanced ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H9#H9\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Influence of mutations on response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have a good response to neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , continuation of treatment after resection for at least three years is recommended. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Adjuvant therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patients with metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although therapy with TKIs has become the first-line treatment for metastatic GIST, surgical resection may be integrated into therapy for the following reasons (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While TKIs control tumor growth in over 80 percent of patients, complete responses are only rarely achieved, and surgical resection remains the only potentially curative therapy for GIST.",
"     </li>",
"     <li>",
"      Most patients who initially respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      eventually acquire resistance via additional mutations in the KIT gene. The median time to progression is approximately two years. Thereafter, the therapeutic alternatives are limited. Thus, although 95 percent of salvage surgeries for metastatic GIST fail, resection of residual disease followed by additional imatinib might delay or prevent the development of resistant clones by reducing tumor burden, and this may prolong the time to disease progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two trials addressing this question were begun in",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00956072\">",
"     Europe",
"    </a>",
"    and in China, but both failed to recruit quickly enough to meet target accrual. In the absence of controlled trials, some general conclusions can be drawn from single institution retrospective studies examining disease control following resection for selected patients with limited metastatic disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, resection appears to benefit responding patients (ie, those who have a partial response, stable disease, or focal progression) but has little to offer those who experience generalized disease progression while receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Resection, even if complete, does not eliminate the need for continued treatment with a TKI therapy. Progression-free survival is significantly shorter in patients who discontinue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      as compared to those who continue the drug after resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This subject, including the data upon which these conclusions are based, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34938?source=see_link&amp;anchor=H15#H15\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\", section on 'Role of surgery in patients with metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTTREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no evidence-based guidelines on what constitutes appropriate follow-up after treatment of a GIST, and there is no consensus on this issue. Relapses most often occur to the liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peritoneum; other sites of metastases, including bone metastases, are rare. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a completely resected GIST tumor, history and physical examination every three to six months for five years, then annually. A CT scan is recommended every three to six months for three to five years, then annually.",
"     </li>",
"     <li>",
"      For patients with more locally advanced or metastatic disease who are receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , history and physical examination, laboratory studies (complete blood count and monitoring of phosphate levels), as well as abdominopelvic CT scan are recommended every three to six months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H12#H12\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Side effects and their management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, posttreatment follow-up guidelines from ESMO emphasize the value of risk assessment in selecting the frequency and specific components of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?32/34/33321/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For high-risk tumors (based upon mitotic count, tumor size, and tumor site), routine follow-up with CT or MRI every three to six months for three years during adjuvant therapy, with tighter clinical followup due to the need to manage the side effects of adjuvant therapy. On cessation of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , routine follow-up with imaging every three months for two years then every six months until five years from stopping adjuvant imatinib, then annually for an additional five years.",
"     </li>",
"     <li>",
"      For low-risk tumors, the usefulness of routine follow-up is not know; if selected, this is carried out with CT or MRI every 6 to 12 months for five years.",
"     </li>",
"     <li>",
"      For very low risk GISTs, routine follow-up is probably not warranted, though the risk of recurrence is not nil.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We stratify our recommendations for posttreatment follow-up according to risk, but do not adhere closely to a specific timetable for patients without high risk disease. For high risk cases, we image every three months for two years, every six months out to five years, and annually to ten years.&nbsp;We reduce the scanning frequency for intermediate and low risk cases, approximating the ESMO guidelines. For very low-risk cases, every other year scanning seems reasonable. We expect that guidelines for follow-up will become more specific as more data become available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal stromal tumors (GISTs) are common mesenchymal neoplasms that affect the Gl tract.",
"     </li>",
"     <li>",
"      Approximately 80 percent of GISTs have mutations in the KIT protooncogene that lead to constitutive activation of KIT, a receptor tyrosine kinase (RTK). A subset of GISTs lacking KIT gene mutations has activating mutations in a related RTK, platelet-derived growth factor receptor-alpha (PDGFRA). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Small molecule tyrosine kinase inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      block signaling via KIT and PDGFRA, thus halting tumor proliferation. The success of these agents in advanced disease has prompted interest in perioperative use in patients with earlier stage disease.",
"     </li>",
"     <li>",
"      We recommend adjuvant treatment with a tyrosine kinase inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      400 mg daily) for a minimum of three years rather than one year in patients who have a completely resected primary high-risk GIST (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1805370\">",
"       'SSG XVIII trial'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The optimal selection of patients who are at sufficiently high risk for recurrence to warrant adjuvant imatinib is not established. Although risk stratification tools are available, based upon tumor size, mitotic rate, location, and in some cases, the presence or absence of tumor rupture, it is not clear what cutoff for disease recurrence should be used to select patients for imatinib. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Estimation of recurrence risk'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Thus, each case must be approached individually, balancing the estimated likelihood of a disease recurrence (based upon anatomic site, size, mitotic rate, and mutation type, if available) with the risks of therapy. Several risk stratification schema are available (",
"      <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef85938 \" href=\"UTD.htm?13/13/13532\">",
"       table 6",
"      </a>",
"      ). In the SSGXVIII trial, high-risk GISTs were defined as &gt;10 cm, mitotic count",
"      <span class=\"nowrap\">",
"       &gt;10/50",
"      </span>",
"      high-power fields (HPF), &gt;5 cm with a mitotic rate",
"      <span class=\"nowrap\">",
"       &gt;5/HPF,",
"      </span>",
"      or a ruptured tumor.",
"      <br/>",
"      <br/>",
"      If a known KIT exon 9 mutation is identified, higher dose imatinib may be considered, but there are no prospective data upon which to base a recommendation either for or against this practice. (See",
"      <a class=\"local\" href=\"#H6457205\">",
"       'Imatinib dosing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H9#H9\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Influence of mutations on response to therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with nonmetastatic but locally advanced unresectable GIST, potentially resectable primary tumors but with the risk of significant morbidity, or potentially resectable metastatic GISTs, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      followed by attempted resection as long as there is no evidence of generalized progression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If possible, such patients should be enrolled on a clinical trial. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Neoadjuvant therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The optimal duration of neoadjuvant imatinib is uncertain, and we individualize this decision based upon drug tolerance, tumor location and extent, and the urgency of surgical treatment.",
"     </li>",
"     <li>",
"      For patients with potentially resectable metastatic disease, aggressive cytoreductive surgery should be offered only to patients whose disease is stable or responding to TK inhibitor therapy, or who have only focal progression (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients with extensive disease progression while on TK inhibitor therapy gain little benefit from surgery, and it is not recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34938?source=see_link&amp;anchor=H15#H15\">",
"       \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\", section on 'Role of surgery in patients with metastatic disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Cytoreductive surgery in this setting often requires extensive potentially morbid procedures such as gastrectomy, hepatectomy, pancreatic resection, and should be carried out in centers of excellence. All patients should resume therapy with a TK inhibitor after resection. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Patients with metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/1\">",
"      Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/2\">",
"      Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/3\">",
"      Huang HY, Li CF, Huang WW, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 2007; 141:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/4\">",
"      Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/5\">",
"      Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/6\">",
"      Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer. American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/8\">",
"      Joensuu H, Vehtari A, Riihim&auml;ki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/9\">",
"      Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/10\">",
"      Gold JS, G&ouml;nen M, Guti&eacute;rrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/11\">",
"      Nilsson B, Sj&ouml;lund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96:1656.",
"     </a>",
"    </li>",
"    <li>",
"     DeMatteo RP, Owzar K, Antonescu CR, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized. primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the US Intergroup phase II trial ACOSOG Z9000 (abstract). Data presented at the 2008 ASCO Gastrointestinal Cancers Symposium, January 25-27, Orlando, FL.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/13\">",
"      Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/14\">",
"      Zhan WH, Wang PZ, Shao YF, et al. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]. Zhonghua Wei Chang Wai Ke Za Zhi 2006; 9:383.",
"     </a>",
"    </li>",
"    <li>",
"     Blackstein ME. Risk assessment for tumor recurrence after surgical resection of localized primary gastropintestinal stromal tumor (GIST): North America intergroup phase III trial ACOSOG Z9001 (abstract). Data presented at the 2010 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 23, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/16\">",
"      Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/17\">",
"      Gronchi A, Judson I, Nishida T, et al. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Eur J Cancer 2009; 45:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/18\">",
"      Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/19\">",
"      Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/20\">",
"      Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007; 14:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/21\">",
"      Hohenberger P, Ronellenfitsch U, Oladeji O, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/22\">",
"      Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/23\">",
"      Chac&oacute;n M, Roca E, Huertas E, et al. CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 2005; 23:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/24\">",
"      L&aacute;ng I, Hitre E, Horv&aacute;th Z, God&eacute;ny M. Case 3. Resection of originally inoperable liver metastases of gastrointestinal stromal tumor after imatinib mesylate therapy. J Clin Oncol 2003; 21:3538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/25\">",
"      Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/26\">",
"      Katz D, Segal A, Alberton Y, et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 2004; 15:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/27\">",
"      Bonvalot S, Eldweny H, P&eacute;choux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/28\">",
"      Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24:2325.",
"     </a>",
"    </li>",
"    <li>",
"     Hohenberger P, Langer C, Pistorius S, et al. Indications and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST) (abstract). J Clin Oncol 2006; 24:520s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/30\">",
"      Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with \"unresectable\" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003; 186:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/31\">",
"      Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/32\">",
"      Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012; 19:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/33\">",
"      Machlenkin S, Pinsk I, Tulchinsky H, et al. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. Colorectal Dis 2011; 13:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/34\">",
"      Van den Abbeele AD, Gatsonis C, de Vries DJ, et al. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med 2012; 53:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/35\">",
"      McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/36\">",
"      DeMatteo RP. Nanoneoadjuvant therapy of gastrointestinal stromal tumor (GIST). Ann Surg Oncol 2009; 16:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/37\">",
"      von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation? Oncology (Williston Park) 2009; 23:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/38\">",
"      Gronchi A, Raut CP. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol 2012; 19:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/39\">",
"      ESMO / European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/34/33321/abstract/40\">",
"      Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006; 187:1267.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7730 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33321=[""].join("\n");
var outline_f32_34_33321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Estimation of recurrence risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Benefit of imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Phase II trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Phase III trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H647861366\">",
"      ACOSOG Z9001",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1805370\">",
"      - SSG XVIII trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H647861381\">",
"      Other completed trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6457205\">",
"      - Imatinib dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11883426\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEOADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - RTOG 0132/ACRIN 6665 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Retrospective series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Response assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary and recommendations of expert groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patients with metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7730\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7730|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/42/40620\" title=\"table 1\">",
"      GIST progn criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/23/36220\" title=\"table 2\">",
"      GIST progn site size mit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/35/8766\" title=\"table 3\">",
"      TNM staging GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/1/10268\" title=\"table 4\">",
"      Dis prog gastric GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/14/10476\" title=\"table 5\">",
"      Dis prog small int GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/13/13532\" title=\"table 6\">",
"      Mod NIH risk strat for GIST incl rupture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34938?source=related_link\">",
"      Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_34_33322="Gastric MALToma Low";
var content_f32_34_33322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68386%7EGAST%2F59651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68386%7EGAST%2F59651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extranodal marginal zone lymphoma (MALT) of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a gastric MALToma (mucosa-associated lymphoid tissue tumor) shows dense, monotonous, lymphoid infiltrate in the lamina propria, and pale- staining cells consistent with marginal zone B-cells surrounding and infiltrating the epithelium (lymphoepithelial lesion).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nancy Lee Harris, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Extranodal marginal zone lymphoma of the stomach (gastric MALToma)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 180px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-grade B cell lymphoma of the MALT-type. Left panel: Infiltrating lymphoma cells with loss of glands and a lymphoepithelial lesion. Right panel: Staining with the monoclonal B cell antibody CD-20 shows that most of the infiltrating cells show B cell reactivity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33322=[""].join("\n");
var outline_f32_34_33322=null;
var title_f32_34_33323="Number LN survival CRC";
var content_f32_34_33323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relationship between number of lymph nodes recovered and outcomes in a meta-analysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        AJCC stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of lymph nodes",
"       </td>",
"       <td class=\"subtitle1\">",
"        5-year disease-free survival",
"       </td>",
"       <td class=\"subtitle1\">",
"        5-year overall survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        II",
"       </td>",
"       <td>",
"        &lt;11",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-20",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;20",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        IIIA-IIIB",
"       </td>",
"       <td>",
"        &lt;11",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-40",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;40",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        IIIC",
"       </td>",
"       <td>",
"        1-35",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;35",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Chang, G, et al. J Natl Cancer Inst 2007; 99:433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33323=[""].join("\n");
var outline_f32_34_33323=null;
var title_f32_34_33324="Guidelines for use of echocardiography in IE";
var content_f32_34_33324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for use of echocardiography in IE",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that TTE or TEE should be performed in patients with native",
"or prosthetic valve IE in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; TTE",
"to detect valvular vegetations with or without positive blood cultures",
"for the diagnosis of IE. Among patients with positive blood cultures,",
"TEE is recommended if TTE is nondiagnostic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; TTE to characterize the hemodynamic severity of the valve lesions in known IE. Among symptomatic patients, TEE is recommended if TTE is nondiagnostic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; TEE as a first-line diagnostic test for prosthetic valve IE and to detect complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; TTE",
"or TEE to assess complications of IE (such as abscesses, perforations,",
"and shunts). TEE is recommended for preoperative evaluation of patients",
"going to surgery unless the indication for surgery is apparent on TTE",
"or imaging will delay urgent surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; TTE",
"for reassessment of high-risk patients, as defined by virulent",
"organism, clinical deterioration, persistent or recurrent fever, a new",
"murmur, or persistent bacteremia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Intraoperative TEE for patients undergoing valve surgery for IE.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or",
"opinion is in favor of the usefulness of TTE or TEE in patients with",
"native or prosthetic valve IE in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; TEE to diagnose possible IE in patients with persistent staphylococcal bacteremia who do not have a known source.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp;",
"Among patients with a prosthetic valve, TTE to diagnose IE in patients",
"with persistent fever without bacteremia or a new murmur.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or",
"opinion is less well established for the usefulness of TTE or TEE in",
"patients with native or prosthetic valve IE in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; TEE to diagnose possible IE in patients with nosocomial staphylococcal bacteremia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp;",
"Among patients with prosthetic valve IE, TTE for reevaluation during",
"antibiotic therapy in the absence of signs of clinical deterioration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that TTE is not useful in patients with native or",
"prosthetic valve IE in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; TTE",
"is not indicated to reevaluate uncomplicated IE (including no valve",
"regurgitation at baseline) during antibiotic therapy in the absence of",
"clinical deterioration, including new physical findings, or persistent",
"fever.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33324=[""].join("\n");
var outline_f32_34_33324=null;
var title_f32_34_33325="Reticulocyte shift";
var content_f32_34_33325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prolongation of reticulocyte maturation time in anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 176px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With worsening anemia and increasing erythropoietin stimulation, bone marrow reticulocytes (left) leave the marrow at an earlier stage in their maturation. This prolongs the maturation time in the circulation from one day to as long as 2.5 days (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hillman, RS, Ault, KA (Eds). Normal erythropoiesis, in: Hematology in Clinical Practice, McGraw-Hill, New York, p. 29.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33325=[""].join("\n");
var outline_f32_34_33325=null;
var title_f32_34_33326="Normal range for coagulation tests in children";
var content_f32_34_33326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Coagulation tests in healthy infants and children, compared with adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Coagulation tests",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Day 1 of life",
"        </p>",
"        <p>",
"         Mean (boundary)",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Day 3 of life",
"        </p>",
"        <p>",
"         Mean (boundary)",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         1 to 12 months",
"        </p>",
"        <p>",
"         Mean (boundary)",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         1 to 5 yr",
"        </p>",
"        <p>",
"         Mean (boundary)",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         6 to 10 yr",
"        </p>",
"        <p>",
"         Mean (boundary)",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         11 to 16 yr",
"        </p>",
"        <p>",
"         Mean (boundary)",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Adult",
"        </p>",
"        <p>",
"         Mean (boundary)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PT(s)*",
"       </td>",
"       <td>",
"        15.6 (14.4-16.4)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        14.9 (13.5-16.4)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        13.1 (11.5-15.3)",
"       </td>",
"       <td>",
"        13.3 (12.1-14.5)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        13.4 (11.7-15.1)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        13.8 (12.7-16.1)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        13 (11.5-14.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        INR",
"       </td>",
"       <td>",
"        1.26 (1.15-1.35)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.20 (1.05-1.35)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.00 (0.86-1.22)",
"       </td>",
"       <td>",
"        1.03 (0.92-1.14)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.04 (0.87-1.2)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.08 (0.97-1.30)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.00 (0.80-1.20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        APTT(s)*",
"       </td>",
"       <td>",
"        38.7 (34.3-44.8)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        36.3 (29.5-42.2)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        39.3 (35.1-46.3)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        37.7 (33.6-46.3)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        37.3 (31.8-43.7)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        39.5 (33.9-46.1)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        33.2 (28.6-38.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrinogen (g/L)",
"       </td>",
"       <td>",
"        2.80 (1.92-3.74)",
"       </td>",
"       <td>",
"        3.30 (2.83-4.01)",
"       </td>",
"       <td>",
"        2.42 (0.82-3.83)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2.82 (1.62-4.01)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        3.04 (1.99-4.09)",
"       </td>",
"       <td>",
"        3.15 (2.12-4.33)",
"       </td>",
"       <td>",
"        3.1 (1.9-4.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor II (U/mL)",
"       </td>",
"       <td>",
"        0.54 (0.41-0.69)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.62 (0.50-0.73)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.90 (0.62-1.03)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.89 (0.70-1.09)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.89 (0.67-1.10)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.90 (0.61-1.07)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.10 (0.78-1.38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor V (U/mL)",
"       </td>",
"       <td>",
"        0.81 (0.64-1.03)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.22 (0.92-1.54)",
"       </td>",
"       <td>",
"        1.13 (0.94-1.41)",
"       </td>",
"       <td>",
"        0.97 (0.67-1.27)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.99 (0.56-1.41)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.89 (0.67-1.41)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.18 (0.78-1.52)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor VII (U/mL)",
"       </td>",
"       <td>",
"        0.70 (0.52-0.88)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.86 (0.67-1.07)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.28 (0.83-1.60)",
"       </td>",
"       <td>",
"        1.11 (0.72-1.50)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.13 (0.70-1.56)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.18 (0.69-2.00)",
"       </td>",
"       <td>",
"        1.29 (0.61-1.99)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor VIII (U/mL)",
"       </td>",
"       <td>",
"        1.82 (1.05-3.29)",
"       </td>",
"       <td>",
"        1.59 (0.83-2.74)",
"       </td>",
"       <td>",
"        0.94 (0.54-1.45)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.10 (0.36-1.85)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.17 (0.52-1.82)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.20 (0.59-2.00)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.60 (0.52-2.90)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        vWF (U/mL)",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        0.82 (0.60-1.20)",
"       </td>",
"       <td>",
"        0.95 (0.44-1.44)",
"       </td>",
"       <td>",
"        1.00 (0.46-1.53)",
"       </td>",
"       <td>",
"        0.92 (0.50-1.58)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor IX (U/mL)",
"       </td>",
"       <td>",
"        0.48 (0.35-0.56)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.72 (0.44-0.97)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.71 (0.43-1.21)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.85 (0.44-1.27)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.96 (0.48-1.45)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.11 (0.64-2.16)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.30 (0.59-2.54)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor X (U/mL)",
"       </td>",
"       <td>",
"        0.55 (0.46-0.67)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.60 (0.46-0.75)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.95 (0.77-1.22)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.98 (0.72-1.25)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.97 (0.68-1.25)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.91 (0.53-1.22)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.24 (0.96-1.71)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor XI (U/mL)",
"       </td>",
"       <td>",
"        0.30 (0.70-0.41)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.57 (0.24-0.79)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.89 (0.62-1.25)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.13 (0.65-1.62)",
"       </td>",
"       <td>",
"        1.13 (0.65-1.62)",
"       </td>",
"       <td>",
"        1.11 (0.65-1.39)",
"       </td>",
"       <td>",
"        1.12 (0.67-1.96)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor XII (U/mL)",
"       </td>",
"       <td>",
"        0.58 (0.43-0.80)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.53 (0.14-0.80)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.79 (0.20-1.35)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.85 (0.36-1.35)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.81 (0.26-1.37)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.75 (0.14-1.17)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.15 (0.35-2.07)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        XIIIa (U/mL)",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        1.08 (0.72-1.43)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.09 (0.65-1.51)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.99 (0.57-1.40)",
"       </td>",
"       <td>",
"        1.05 (0.55-1.55)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        XIIIs (U/mL)",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        1.13 (0.69-1.56)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.16 (0.77-1.54)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.02 (0.60-1.43)",
"       </td>",
"       <td>",
"        0.97 (0.57-1.37)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All factors except fibrinogen are expressed as units per milliliter, where pooled plasma contains 1.0 U/mL. All data are expressed as the mean, followed by the upper and lower boundary encompassing 95 percent of the population. Between 20 and 67 samples were assayed for each value for each age group. Some measurements were skewed due to a disproportionate number of high values. The lower limit, which excludes the lower 2.5 percent of the population, is given.",
"    <div class=\"footnotes\">",
"     PT: prothrombin time; APTT: activated partial thromboplastin time; VIII: factor VIII procoagulant; vWF: von Willebrand factor; n/a: data not available.",
"     <br>",
"      * Normal range for PT and aPTT should be based upon the standards set by individual clinical laboratories.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Denotes values that are significantly different from adults.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data on vWF, XIIIa and XIIIs from: Andrew M, Vegh P, Johnston M, et al. Maturation of the Hemostatic System During Childhood. Blood 1992; 80:1999.",
"     <br>",
"      Remaining data from: Monagle P, Barnes C, Ignjatovic V, Furmedge J, et al. Developmental Haemostasis. Thrombosis and Haemostasis 2006; 95:362.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33326=[""].join("\n");
var outline_f32_34_33326=null;
var title_f32_34_33327="Dry AMD with drusen";
var content_f32_34_33327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dry type age-related macular degeneration (AMD) with drusen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small, bright yellow drusen are visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the Massachusetts Eye &amp; Ear Infirmary, Photographer, David Walsh.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_34_33327=[""].join("\n");
var outline_f32_34_33327=null;
